Subcutaneous methadone in terminally ill patients: Manageable local toxicity

Journal of Pain and Symptom Management

Volumn 18, Issue 1, 1999, Pages 49-52

  Mathew, Paul ^a   Storey, Porter ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b EAST TEXAS MEDICAL CENTER   (United States)

Author keywords

Analgesia; Dexamethasone; Local toxicity; Methadone; Subcutaneous infusion; Uncontrolled pain

Indexed keywords

DEXAMETHASONE; HYDROMORPHONE; METHADONE; MORPHINE;

ADULT; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; COST CONTROL; DRUG EFFICACY; DRUG INFUSION; ERYTHEMA; FEMALE; HOSPICE; HUMAN; INFUSION PUMP; MALE; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; SYRINGE; TERMINAL DISEASE;

ADULT; ANALGESICS, OPIOID; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHADONE; MIDDLE AGED; RETROSPECTIVE STUDIES; TERMINALLY ILL;

EID: 0032808428     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(99)00020-2     Document Type: Article

References (14)

1. Ripamonti C., Zecca E., Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 70:1997;109-115.
2. Morley J.S., Watt J.W.G., Wells J.C., Miles J.B. Methadone in pain uncontrolled by morphine. Lancet. 342:1993;1243.
3. Galer B.S., Coyle N., Pasternak G.W., Portenoy R.K. Individual variability in the response to different opioids. report of five cases Pain. 49:1992;87-91.
4. Crews J.C., Sweeney N.J., Denson D.D. Clinical efficacy of methadone in patients refractory to other μ-opioid receptor agonist analgesics for management of terminal cancer pain. Cancer. 72:1993;2266-2272.
5. Kolassa M. Guidance for clinicians in discerning and comparing the price of pharmaceutical agents. J Pain Symptom Manage. 9:1994;235-243.
6. Storey P., Hill H.H., St Louis RH, Tarver EE. Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage. 5:1990;33-41.
7. Bruera E., Brenneis C., Michaud M., Chadwick S., MacDonald R.N. Continuous sc infusion of narcotics using a portable disposable device in patients with advanced cancer. Cancer Treat Rep. 71:1987;635-637.
8. Bruera E., Fainsinger R., Moore M., Thibault R., Spoldi E., Ventafridda V. Local toxicity with subcutaneous methadone. Experience of two centers. Pain. 45:1991;141-143.
9. Bohrer H., Schmidt H. Local toxicity with subcutaneous methadone (Letter). Pain. 50:1992;373.
10. Adams E., Cruz L., Deachman M.J., Zamora E. Focal subdermal toxicity with subcutaneous opioid infusion in patients with cancer pain. J Pain Symptom Manage. 4:1989;31-33.
11. Twycross R.G., Lack S.A. Therapeutics in Terminal Cancer,2nd. 1990;26-37 Churchill Livingston, Singapore.
12. Shvartzman P., Bonneh D. Local skin irritation in the course of subcutaneous morphine infusion. a challenge J Palliative Care. 10:1994;44-45.
13. Bruera E., Legris M.A., Kuehn N., Miller M.J. Hypodermoclysis for the administration of fluids and narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage. 5:1990;218-220.
14. Bruera E., Stoutz N.D., Fainsinger R.L., Spachynski K., Suarez-Almazor M., Hanson J. Comparison of two different concentrations of hyaluronidase in patients receiving one-hour infusions of hypodermoclysis. J Pain Symptom Manage. 10:1995;505-509.